Global Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone), Distribution Channel (Offline, Online), End-User - Forecast 2024-2030- Product Image

Sale

Global Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone), Distribution Channel (Offline, Online), End-User - Forecast 2024-2030

Report
181 Pages
March 2024
Region: Global
360iResearch™
ID: 5889780

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The Idiopathic Pulmonary Fibrosis Market size was estimated at USD 3.46 billion in 2023, USD 3.65 billion in 2024, and is expected to grow at a CAGR of 5.47% to reach USD 5.03 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Idiopathic Pulmonary Fibrosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Idiopathic Pulmonary Fibrosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Idiopathic Pulmonary Fibrosis Market, highlighting leading vendors and their innovative profiles. These include Algernon Pharmaceuticals Inc., Alkem Laboratories Ltd., AstraZeneca PLC, Avalyn Pharma Inc., Biogen, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Camber Pharmaceuticals, Inc. by Hetero Labs Limited, Chemo Healthcare Pvt. Ltd., Cipla Limited, Dr Reddy's Laboratories Ltd., FibroGen, Inc., Galapagos NV, Glenmark Pharmaceuticals Ltd., GNI Group Ltd., Horizon Therapeutics PLC by Amgen Inc., Lupin Ltd., MediciNova, Inc., Merck & Co., Mission Therapeutics, MSN Laboratories Private Limited, Sandoz International GmbH, Sanify Healthcare Private Limited, Shionogi & Co., Ltd., and Teva Pharmaceuticals, Inc.

Market Segmentation & Coverage

This research report categorizes the Idiopathic Pulmonary Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Nintedanib
- Pirfenidone
Distribution Channel
- Offline
- Online
End-User
- Ambulatory Surgical Centers
- Home Care Facilities
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Idiopathic Pulmonary Fibrosis Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Idiopathic Pulmonary Fibrosis Market?
What are the technology trends and regulatory frameworks in the Idiopathic Pulmonary Fibrosis Market?
What is the market share of the leading vendors in the Idiopathic Pulmonary Fibrosis Market?
Which modes and strategic moves are suitable for entering the Idiopathic Pulmonary Fibrosis Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Idiopathic Pulmonary Fibrosis Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of idiopathic pulmonary fibrosis
5.1.1.2. Advancements in the medical and diagnostic technology
5.1.2. Restraints
5.1.2.1. High cost of therapies and treatments
5.1.3. Opportunities
5.1.3.1. Innovations in the precision medicine and development of targeted therapies
5.1.3.2. Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
5.1.4. Challenges
5.1.4.1. Concerns associated with side-effects and potential risk of IPF treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Idiopathic Pulmonary Fibrosis Market, by Drug Type

6.1. Introduction
6.2. Nintedanib
6.3. Pirfenidone

7. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

7.1. Introduction
7.2. Offline
7.3. Online

8. Idiopathic Pulmonary Fibrosis Market, by End-User

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Home Care Facilities
8.4. Hospitals & Clinics

9. Americas Idiopathic Pulmonary Fibrosis Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Idiopathic Pulmonary Fibrosis Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Algernon Pharmaceuticals Inc.
13.1.2. Alkem Laboratories Ltd.
13.1.3. AstraZeneca PLC
13.1.4. Avalyn Pharma Inc.
13.1.5. Biogen, Inc.
13.1.6. Boehringer Ingelheim International GmbH
13.1.7. Bristol Myers Squibb
13.1.8. Camber Pharmaceuticals, Inc. by Hetero Labs Limited
13.1.9. Chemo Healthcare Pvt. Ltd.
13.1.10. Cipla Limited
13.1.11. Dr Reddy's Laboratories Ltd.
13.1.12. FibroGen, Inc.
13.1.13. Galapagos NV
13.1.14. Glenmark Pharmaceuticals Ltd.
13.1.15. GNI Group Ltd.
13.1.16. Horizon Therapeutics PLC by Amgen Inc.
13.1.17. Lupin Ltd.
13.1.18. MediciNova, Inc.
13.1.19. Merck & Co.
13.1.20. Mission Therapeutics
13.1.21. MSN Laboratories Private Limited
13.1.22. Sandoz International GmbH
13.1.23. Sanify Healthcare Private Limited
13.1.24. Shionogi & Co., Ltd.
13.1.25. Teva Pharmaceuticals, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET RESEARCH PROCESS
FIGURE 2. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2023 VS 2030
FIGURE 3. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET DYNAMICS
FIGURE 7. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 9. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 12. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 26. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 29. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 143. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 144. IDIOPATHIC PULMONARY FIBROSIS MARKET LICENSE & PRICING

Companies Mentioned

Algernon Pharmaceuticals Inc.
Alkem Laboratories Ltd.
AstraZeneca PLC
Avalyn Pharma Inc.
Biogen, Inc.
Boehringer Ingelheim International GmbH
Bristol Myers Squibb
Camber Pharmaceuticals, Inc. by Hetero Labs Limited
Chemo Healthcare Pvt. Ltd.
Cipla Limited
Dr Reddy's Laboratories Ltd.
FibroGen, Inc.
Galapagos NV
Glenmark Pharmaceuticals Ltd.
GNI Group Ltd.
Horizon Therapeutics PLC by Amgen Inc.
Lupin Ltd.
MediciNova, Inc.
Merck & Co.
Mission Therapeutics
MSN Laboratories Private Limited
Sandoz International GmbH
Sanify Healthcare Private Limited
Shionogi & Co., Ltd.
Teva Pharmaceuticals, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	181
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 3.65 Billion
Forecasted Market Value ( USD ) by 2030	$ 5.03 Billion
Compound Annual Growth Rate	5.4%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,802GBP €3624EUR$3,749USD£3,113GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,549GBP €4591EUR$4,749USD£3,944GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,297GBP €5558EUR$5,749USD£4,774GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,044GBP €6525EUR$6,749USD£5,605GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7613EUR$7,874USD£6,539GBP €8458EUR$8,749USD£7,265GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Idiopathic Pulmonary Fibrosis (IPF) Market (2023 Edition): Analysis By Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Parenteral, Others), Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

Idiopathic Pulmonary Fibrosis Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Type, Distribution Channel, and Geography

Idiopathic Pulmonary Fibrosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Idiopathic Pulmonary Fibrosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

Global Idiopathic Pulmonary Fibrosis Treatment Market Report and Forecast 2023-2031